Monitor whether the company's recent acquisitions and mezzanine loans can reverse the declining earnings trend in 2026. The maintained dividend and strong balance sheet provide stability, but investors should watch for improvements in core profitability metrics.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $25.97entry
- T+1 · 9mo ago −1.36%α −0.82% · $25.61
- T+5 · 9mo ago −4.43%α −3.33% · $24.82
- T+20 · 8mo ago −10.08%α −4.85% · $23.35
- T+60 · 6mo ago +16.49%α +9.54% · $30.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sila Realty Trust reported mixed results for 2025, with declining GAAP net income and AFFO per share year-over-year despite growth in Cash NOI and a strong acquisition pipeline. Full-year net income dropped 22.5% to $33.1 million ($0.60/share) from $42.7 million ($0.75/share), while AFFO decreased 7.8% to $120.9 million ($2.18/share). The company maintained its dividend at $1.60 annualized and held a solid balance sheet with $481.3 million in liquidity and a 3.9x net debt to EBITDAre ratio.
Key Financial Metrics
Key Facts
- GAAP net income for 2025 was $33.1 million ($0.60/share), down from $42.7 million ($0.75/share) in 2024
- AFFO for 2025 was $120.9 million ($2.18/share), down from $131.1 million ($2.31/share) in 2024
- Cash NOI increased 0.8% to $169.9 million in 2025 from $168.6 million in 2024
- Company acquired six healthcare properties for $148.9 million and funded $17.5 million in mezzanine loans
- Dividend maintained at $0.40 per quarter ($1.60 annualized) with 72.6% AFFO payout ratio
- Balance sheet strength with $481.3 million liquidity and 3.9x net debt to EBITDAre ratio
Financial Impact
Revenue increased 5.7% to $197.5 million, but net income declined 22.5% to $33.1 million. AFFO per share decreased 5.6% to $2.18.
Segment Breakdown
| Segment |
|---|
| Inpatient Rehabilitation Facility |
| Medical Outpatient Building |
| Surgical and Specialty Facilities |
Risk Factors
- Continuing decline in net income and AFFO per share despite revenue growth
- Potential for further earnings compression if acquisition integration underperforms
- Dependence on healthcare sector which faces regulatory and reimbursement risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001567925-26-000005 |
| Exhibit: exhibi3.htm | 0001567925-26-000005 |
| Document: cik0001567925-20260224.htm | 0001567925-26-000005 |
| Document: 0001567925-26-000005-index-headers.html | 0001567925-26-000005 |
| Document: 0001567925-26-000005-index.html | 0001567925-26-000005 |
| Document: 0001567925-26-000005.txt | 0001567925-26-000005 |
Track record
11 reports on SILA
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +0.46% at T+20 after the Apr 20, 2026 report. 3 of 5 went positive at some point.
Filters
- Jul 13, 202618w ago 15-12G Neutral 4/10 No price data
- Jul 1, 202619w ago 25-NSE Neutral 7/10 Entry $30.37 No price data
- Jun 17, 202621w ago DEFA14A Neutral 4/10 Entry $30.30 No price data
- Jun 17, 202621w ago 8-K Neutral 3/10 Entry $30.30 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 3/10 Entry $30.27 No price data
- May 22, 202625w ago DEFM14A Bullish 7/10 Entry $30.21 to $30.34 ▲ +0.43% +1.85% vs SPY
- May 7, 202627w ago 8-K Bullish 9/10 Entry $30.58 to $30.25 ▼ −1.08% −1.10% vs SPY
- May 5, 202627w ago PREM14A Bullish 7/10 Entry $30.58 to $30.24 ▼ −1.11% −3.89% vs SPY
- Apr 20, 202630w ago DEFA14A Bullish 8/10 Entry $30.40 to $30.54 ▲ +0.46% −3.74% vs SPY
- Apr 20, 202630w ago 8-K Bullish 8/10 Entry $30.40 to $30.54 ▲ +0.46% −3.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers